DE69832970D1 - HUMANIZED ANTIBODIES AND METHOD FOR THEIR MANUFACTURE - Google Patents

HUMANIZED ANTIBODIES AND METHOD FOR THEIR MANUFACTURE

Info

Publication number
DE69832970D1
DE69832970D1 DE69832970T DE69832970T DE69832970D1 DE 69832970 D1 DE69832970 D1 DE 69832970D1 DE 69832970 T DE69832970 T DE 69832970T DE 69832970 T DE69832970 T DE 69832970T DE 69832970 D1 DE69832970 D1 DE 69832970D1
Authority
DE
Germany
Prior art keywords
vegf
manufacture
humanized antibodies
inhibit
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832970T
Other languages
German (de)
Other versions
DE69832970T2 (en
Inventor
A Wells
Manuel Baca
G Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25264594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69832970(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69832970D1 publication Critical patent/DE69832970D1/en
Application granted granted Critical
Publication of DE69832970T2 publication Critical patent/DE69832970T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)

Abstract

Humanized and variant anti-VEGF antibodies and various uses therefore are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro, and inhibit tumor growth in vivo.
DE69832970T 1997-04-07 1998-04-03 HUMANIZED ANTIBODIES AND METHOD FOR THEIR MANUFACTURE Expired - Lifetime DE69832970T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83350497A 1997-04-07 1997-04-07
US833504 1997-04-07
PCT/US1998/006724 WO1998045332A2 (en) 1997-04-07 1998-04-03 Humanized antibodies and methods for forming humanized antibodies

Publications (2)

Publication Number Publication Date
DE69832970D1 true DE69832970D1 (en) 2006-02-02
DE69832970T2 DE69832970T2 (en) 2006-08-10

Family

ID=25264594

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69832970T Expired - Lifetime DE69832970T2 (en) 1997-04-07 1998-04-03 HUMANIZED ANTIBODIES AND METHOD FOR THEIR MANUFACTURE
DE69842174T Expired - Lifetime DE69842174D1 (en) 1997-04-07 1998-04-03 Method of producing humanized antibodies by randomized mutagenesis
DE69841815T Expired - Lifetime DE69841815D1 (en) 1997-04-07 1998-04-03 Anti-VEGF antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69842174T Expired - Lifetime DE69842174D1 (en) 1997-04-07 1998-04-03 Method of producing humanized antibodies by randomized mutagenesis
DE69841815T Expired - Lifetime DE69841815D1 (en) 1997-04-07 1998-04-03 Anti-VEGF antibody

Country Status (22)

Country Link
EP (6) EP3260468A1 (en)
JP (1) JP4191258B2 (en)
KR (2) KR100856995B1 (en)
CN (6) CN101210050B (en)
AT (4) ATE476664T1 (en)
AU (1) AU740738B2 (en)
BR (1) BRPI9809388B8 (en)
CA (1) CA2286397C (en)
CY (3) CY1111345T1 (en)
DE (3) DE69832970T2 (en)
DK (4) DK1787999T3 (en)
ES (4) ES2380575T3 (en)
HK (7) HK1025338A1 (en)
IL (3) IL132239A0 (en)
LT (1) LTC0973804I2 (en)
NO (3) NO325823B1 (en)
NZ (1) NZ500077A (en)
PT (5) PT973804E (en)
SI (5) SI1695985T1 (en)
TR (1) TR199902818T2 (en)
WO (1) WO1998045332A2 (en)
ZA (2) ZA982907B (en)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
IL132239A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Humanized antibodies and methods for forming humanized antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
EP1650220B1 (en) 1997-04-07 2007-09-05 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
PT2016951E (en) 1998-03-17 2012-09-27 Genentech Inc Polypeptides homologous to vegf and bmp1
WO2000029584A1 (en) 1998-11-18 2000-05-25 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
DE60011612T2 (en) 1999-04-28 2005-07-07 Board of Regents, The University of Texas System, Austin Compositions and methods of cancer treatment by the selective inhibition of VEGF
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
ES2281413T3 (en) 2000-04-21 2007-10-01 Fuso Pharmaceutical Industries Ltd. NEW COLLECTORS.
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003216250A1 (en) * 2002-02-11 2003-09-04 Genentech, Inc. Antibody variants with faster antigen association rates
WO2003105782A2 (en) 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP2248829A1 (en) 2003-05-30 2010-11-10 Genentech, Inc. Treatment with anti-VEGF antibodies
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
WO2005056781A1 (en) 2003-12-02 2005-06-23 Institut Pasteur Use of proteins and peptides coded by the genome of a novel strain of sars-associated coronavirus
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2172482A1 (en) 2004-07-20 2010-04-07 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
SI1802334T1 (en) 2004-10-21 2012-12-31 Genentech, Inc. Method for treating intraocular neovascular diseases
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
EP1973950B1 (en) 2006-01-05 2014-09-17 Genentech, Inc. Anti-ephb4 antibodies and methods using the same
US8197815B2 (en) 2006-01-20 2012-06-12 Genentech, Inc. Anti-EphrinB2 antibodies and methods using same
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
ES2514495T3 (en) * 2006-05-25 2014-10-28 Glaxo Group Limited Humanized anti-interleukin-18 modified antibodies
US7803377B2 (en) 2006-06-06 2010-09-28 Genentech, Inc. Anti-DLL4 antibodies and methods using same
CN1903880B (en) * 2006-08-02 2010-05-12 中国人民解放军军事医学科学院基础医学研究所 Antitumour vascular endothelial growth factor VEGF-E antigen, its coding gene and application
ES2392630T3 (en) 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Anti-tumor therapy with anti-VEGF antibodies
CN101148474B (en) * 2006-09-21 2014-06-11 上海杰隆生物工程股份有限公司 Human resource vessel endothelium growth factor monoclonal antibody and preparation method thereof
JP2010513566A (en) 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド Treatment of early stage tumors with VEGF-specific antagonists for adjuvant and neoadjuvant therapy
US8318163B2 (en) 2007-05-17 2012-11-27 Genentech, Inc. Anti-pan neuropilin antibody and binding fragments thereof
ES2469743T3 (en) 2007-05-17 2014-06-18 Genentech, Inc. Inhibition of tumor metastasis by anti neuropilin 2 antibodies
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
MX2010004740A (en) 2007-10-30 2010-05-27 Genentech Inc Antibody purification by cation exchange chromatography.
TW200924796A (en) 2007-11-09 2009-06-16 Genentech Inc Activin receptor-like kinase-1 compositions and methods of use
TWI468417B (en) 2007-11-30 2015-01-11 Genentech Inc Anti-vegf antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
RU2531523C3 (en) * 2008-06-25 2022-05-04 Новартис Аг STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2739429C (en) 2008-10-14 2020-12-22 Lisa A. Damico Immunoglobulin variants and uses thereof
BRPI0921469B1 (en) 2008-11-03 2022-01-18 Molecular Partners Ag BINDING PROTEINS THAT INHIBIT INTERACTION WITH THE VEGF-A RECEPTOR, PHARMACEUTICAL COMPOSITION
HUE024872T2 (en) 2008-11-22 2016-02-29 Hoffmann La Roche Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
CA2746120A1 (en) 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
KR101431318B1 (en) 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
US20120093811A1 (en) * 2009-04-03 2012-04-19 Simmonds Jason W Anti-vegf-d antibodies
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
WO2010129904A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG177265A1 (en) * 2009-06-17 2012-02-28 Abbott Biotherapeutics Corp Anti-vegf antibodies and their uses
MX2012000620A (en) 2009-07-13 2012-01-27 Genentech Inc Diagnostic methods and compositions for treatment of cancer.
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
NZ597531A (en) 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
TW201431558A (en) 2009-08-15 2014-08-16 建南德克公司 Anti-angiogenesis therapy for the treatment of previously treated breast cancer
MX2012002862A (en) 2009-09-11 2012-08-15 Genentech Inc Method to identify a patient with an increased likelihood of responding to an anti-cancer agent.
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
BR112012005670A2 (en) 2009-09-17 2017-01-10 Hoffmann La Roche '' method for identifying a cancer patient who may benefit from antiagiogenic therapy, method for predicting a cancer patient's responsiveness to antiangiogenic therapy, use of an anti-vegf antibody to improve the effect of treating a cancer patient, method or use, useful kit for performing the method, use of a protein or usom kit useful for performing the method, use of a protein or oligonucleotide or polynecleotide matrix to determine the level of bfgf expression in a method and kit or use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
CN102051396B (en) * 2009-11-04 2014-07-16 无锡天演生物技术有限公司 Goose-array type localized random mutation method and application thereof in monoclonal antibody molecular evolution technology
JP5818805B2 (en) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド Anti-VEGF-C antibody and method of use thereof
MY159156A (en) 2009-12-21 2016-12-15 Genentech Inc Antibody formulation
KR20120107503A (en) 2009-12-23 2012-10-02 제넨테크, 인크. Anti-bv8 antibodies and uses thereof
FR2955773B1 (en) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
MA34059B1 (en) 2010-02-23 2013-03-05 Genentech Inc ANTI-ANGIOGENIC THERAPY FOR THE TREATMENT OF OVARIAN CANCER
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
CN102863533B (en) * 2010-06-21 2013-12-11 中国科学技术大学 Method for humanized reform for antibody
EP2591004A1 (en) 2010-07-09 2013-05-15 F.Hoffmann-La Roche Ag Anti-neuropilin antibodies and methods of use
MX2013000675A (en) 2010-07-19 2013-04-03 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
CN104569395A (en) 2010-07-19 2015-04-29 霍夫曼-拉罗奇有限公司 Method to identify patient with increased likelihood of responding to anti-cancer therap
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
KR101586128B1 (en) 2010-08-24 2016-01-15 에프. 호프만-라 로슈 아게 Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX2013005388A (en) 2010-11-15 2013-11-04 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies.
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CN103620032B (en) * 2010-12-31 2016-02-24 生物蛋白有限公司 The quick humanization of antibody
CN103403025B (en) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 Monovalent antigen binding protein
ES2549638T3 (en) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Antigen binding proteins
CN103476795B (en) 2011-03-29 2016-07-06 罗切格利卡特公司 Antibody Fc variant
KR102021157B1 (en) 2011-04-01 2019-09-11 제넨테크, 인크. Combinations of akt inhibitor compounds and abiraterone, and methods of use
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
WO2013009767A2 (en) 2011-07-12 2013-01-17 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
EP2744825A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
JP6563197B2 (en) 2012-03-13 2019-08-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy for the treatment of ovarian cancer
KR102129636B1 (en) 2012-05-31 2020-07-03 제넨테크, 인크. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
RU2639287C2 (en) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications
JP6309002B2 (en) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Methods and uses for making antibody Fc region conjugates comprising at least one binding entity that specifically binds to a target
DK3495387T3 (en) 2012-07-13 2021-11-08 Roche Glycart Ag Bispecific anti-VEGF / anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
BR112015002681A2 (en) 2012-08-07 2018-08-28 Genentech Inc method to treat a patient and kit
CN104884056A (en) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 Compounds and methods for producing a conjugate
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
FR2998579B1 (en) 2012-11-27 2015-06-19 Commissariat Energie Atomique METHOD FOR OBTAINING ANTIGEN-SPECIFIC HUMAN ANTIBODIES BY IN VITRO IMMUNIZATION
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
NZ751452A (en) 2013-03-13 2020-04-24 Genentech Inc Antibody formulations
AU2014249243C1 (en) 2013-03-13 2019-08-08 Imaginab, Inc. Antigen binding constructs to CD8
BR112015029145A2 (en) 2013-05-23 2017-09-19 Glaxosmithkline Ip No 2 Ltd USES OF A FIBROBLAST GROWTH FACTOR 1 (FGFR1) RECEPTOR EXTRACELLULAR DOMAIN (ECD) AND PATIENT IDENTIFICATION METHODS
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
EP3851118A1 (en) 2013-10-25 2021-07-21 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
WO2015071348A1 (en) 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2015085847A1 (en) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EA201600473A1 (en) 2013-12-20 2016-12-30 Ф. Хоффманн-Ля Рош Аг HUMANIZED ANTIBODIES TO Tau (PS422) AND METHODS OF APPLICATION
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CN106132439A (en) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 Comprise antiangiogenic agent and OX40 combines the combination treatment of agonist
CA2947456C (en) 2014-05-12 2023-03-14 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
WO2015187428A1 (en) 2014-06-06 2015-12-10 Redwood Bioscience, Inc. Anti-her2 antibody-maytansine conjugates and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10166273B2 (en) 2014-08-12 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
KR20170057339A (en) 2014-09-15 2017-05-24 제넨테크, 인크. Antibody formulations
BR112017006664A2 (en) 2014-10-03 2017-12-26 Novartis Ag combination therapies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
UY36351A (en) 2014-10-14 2016-06-01 Novartis Ag ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
KR20170094165A (en) 2014-12-23 2017-08-17 제넨테크, 인크. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
JP2018518483A (en) 2015-06-08 2018-07-12 ジェネンテック， インコーポレイテッド Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
EP3313877B1 (en) * 2015-06-24 2020-06-03 H. Hoffnabb-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN114272371A (en) 2015-07-29 2022-04-05 诺华股份有限公司 Combination therapy comprising anti-PD-1 antibody molecules
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
KR102162324B1 (en) 2015-10-30 2020-10-07 제넨테크, 인크. Anti-HtrA1 antibodies and methods of use thereof
CN108697791B (en) 2015-11-03 2022-08-23 詹森生物科技公司 Antibodies that specifically bind to PD-1 and uses thereof
US20190209697A1 (en) 2015-11-05 2019-07-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
BR112018009953B1 (en) 2015-11-18 2024-03-05 Formycon Ag STERILIZED PRE-FILLED PHARMACEUTICAL SYRINGE, AND, KIT
AU2016356717B2 (en) 2015-11-18 2022-09-29 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
CN108290004A (en) 2015-11-18 2018-07-17 福尔密孔股份公司 Pre-filled plastic injector containing VEGF antagonist
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antibodies and conjugates thereof
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
CN105481981B (en) * 2016-01-27 2019-03-19 中国人民解放军第二军医大学 Target VEGF bispecific antibody and application thereof
KR20190003958A (en) 2016-04-15 2019-01-10 제넨테크, 인크. Treatment and monitoring of cancer
CA3020718A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
JP2019524706A (en) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Use of human epididymis protein 4 (HE4) to assess responsiveness of MUC16 positive cancer treatment
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
EP3496752B1 (en) 2016-08-12 2022-05-18 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
US10919958B2 (en) * 2016-08-23 2021-02-16 Medimmune Limited Anti-VEGF-A antibodies and uses thereof
CA3049656A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
KR20190134631A (en) 2017-03-01 2019-12-04 제넨테크, 인크. How to diagnose and treat cancer
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
CN118307674A (en) 2017-06-22 2024-07-09 诺华股份有限公司 Antibody molecules against CD73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
CN112203679A (en) 2018-03-02 2021-01-08 科达制药股份有限公司 IL-6 antibodies and fusion constructs and conjugates thereof
CN112074535A (en) 2018-03-09 2020-12-11 艾吉纳斯公司 anti-CD 73 antibodies and methods of use thereof
CN111989095A (en) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 Method for preventing or treating side effects of tumor therapy
JP7361727B2 (en) 2018-05-24 2023-10-16 ヤンセン バイオテツク，インコーポレーテツド PSMA binder and its use
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019361983A1 (en) 2018-10-18 2021-05-20 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
US20220185875A1 (en) 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP3956022A1 (en) 2019-04-19 2022-02-23 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
KR20220004744A (en) 2019-05-03 2022-01-11 제넨테크, 인크. Methods of Treating Cancer Using Anti-PD-L1 Antibodies
WO2020227554A1 (en) * 2019-05-09 2020-11-12 Genentech, Inc. Methods of making antibodies
US11661454B2 (en) 2019-08-09 2023-05-30 Anhui Biox Vision Biological Technology Co., Ltd. Anti-VEGF-PD1 bispecific antibody with novel structure and use thereof
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115605507A (en) 2020-03-13 2023-01-13 基因泰克公司（Us） Anti-interleukin-33 antibodies and uses thereof
AU2021243864A1 (en) 2020-03-27 2022-11-03 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN113461824A (en) 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 Platform for constructing multispecific antibody
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
FR3110838B1 (en) 2020-05-28 2022-06-24 Commissariat Energie Atomique IMMUNOMODULATOR COMPLEX AND ITS APPLICATIONS FOR THERAPY
US20220023405A1 (en) 2020-06-30 2022-01-27 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN114106190A (en) 2020-08-31 2022-03-01 普米斯生物技术(珠海)有限公司 anti-VEGF/PD-L1 bispecific antibody and application thereof
EP4243828A1 (en) 2020-11-13 2023-09-20 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
WO2022162518A2 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
KR20230157388A (en) 2021-03-12 2023-11-16 멘두스 비.브이. Methods of vaccination and uses of CD47 blockade
JP2024516230A (en) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド Therapeutic and diagnostic methods and compositions for cancer
KR20240028452A (en) 2021-07-02 2024-03-05 제넨테크, 인크. Methods and compositions for treating cancer
IL309120A (en) 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for treating cancer
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023144973A1 (en) 2022-01-27 2023-08-03 中外製薬株式会社 Pharmaceutical composition containing anti-pd-l1 antibody to be used in combination with anti-vegf antibody and paclitaxel
WO2023142996A1 (en) 2022-01-28 2023-08-03 上海岸阔医药科技有限公司 Method for preventing or treating disease or disorder associated with antineoplastic agent
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2001774C (en) * 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2108147C (en) * 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
JP3571337B2 (en) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド Homozygous gene conjugation by gene targeting
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP1167384B1 (en) * 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
DE122004000036I1 (en) 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma.
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
AU696764B2 (en) * 1994-03-08 1998-09-17 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
IL132239A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Humanized antibodies and methods for forming humanized antibodies

Also Published As

Publication number Publication date
DK1787999T3 (en) 2010-11-15
CY1111345T1 (en) 2015-08-05
EP3260468A1 (en) 2017-12-27
KR20010006116A (en) 2001-01-26
TR199902818T2 (en) 2000-05-22
ATE541586T1 (en) 2012-02-15
CN101838328A (en) 2010-09-22
EP1695985B1 (en) 2011-03-09
CN101665536B (en) 2013-07-03
EP0971959B1 (en) 2005-12-28
EP2301580A9 (en) 2011-09-14
EP1695985A3 (en) 2006-11-22
EP2336190A3 (en) 2011-10-05
WO1998045332A3 (en) 1998-12-03
IL132239A0 (en) 2001-03-19
SI0973804T1 (en) 2007-06-30
HK1149501A1 (en) 2011-10-07
IL175906A0 (en) 2006-10-05
DK1695985T3 (en) 2011-06-14
NO2017039I2 (en) 2018-08-28
KR100794454B1 (en) 2008-01-16
CN101210050B (en) 2010-12-08
CN104231078A (en) 2014-12-24
ES2256935T3 (en) 2006-07-16
KR20010006115A (en) 2001-01-26
CN1191276C (en) 2005-03-02
DE69842174D1 (en) 2011-04-21
NZ500077A (en) 2001-10-26
PT971959E (en) 2006-05-31
CN101210050A (en) 2008-07-02
NO994870D0 (en) 1999-10-06
CY1111520T1 (en) 2015-08-05
NO994870L (en) 1999-12-06
CA2286397C (en) 2011-02-15
BRPI9809388B8 (en) 2021-05-25
ATE501170T1 (en) 2011-03-15
HK1204329A1 (en) 2015-11-13
NO325823B1 (en) 2008-07-21
AU7102398A (en) 1998-10-30
PT1695985E (en) 2011-06-06
LTPA2007004I1 (en) 2019-12-27
CN1259961A (en) 2000-07-12
PT2301580E (en) 2012-05-02
NO2017039I1 (en) 2017-08-01
EP2301580B1 (en) 2012-01-18
ZA982907B (en) 1998-10-09
PT973804E (en) 2007-03-30
LTC0973804I2 (en) 2020-04-27
SI1695985T1 (en) 2011-06-30
ES2349559T3 (en) 2011-01-05
CA2286397A1 (en) 1998-10-15
BR9809388A (en) 2000-06-13
NO2019045I1 (en) 2019-12-11
CN101665536A (en) 2010-03-10
EP2338915A2 (en) 2011-06-29
IL175906A (en) 2010-05-31
CN101210051B (en) 2012-12-26
CN101210051A (en) 2008-07-02
EP2338915A3 (en) 2011-10-12
BR9809388B1 (en) 2013-06-04
PT1787999E (en) 2010-11-11
CY1112757T1 (en) 2016-02-10
SI2301580T1 (en) 2012-05-31
EP2301580A1 (en) 2011-03-30
EP2336190A2 (en) 2011-06-22
HK1139425A1 (en) 2010-09-17
HK1114621A1 (en) 2008-11-07
ATE476664T1 (en) 2010-08-15
ES2361267T3 (en) 2011-06-15
ATE314395T1 (en) 2006-01-15
DK0971959T3 (en) 2006-05-15
JP2001502922A (en) 2001-03-06
SI0971959T1 (en) 2006-06-30
DK2301580T3 (en) 2012-05-14
IL132240A (en) 2006-09-05
DE69832970T2 (en) 2006-08-10
JP4191258B2 (en) 2008-12-03
SI1787999T1 (en) 2010-12-31
WO1998045332A2 (en) 1998-10-15
HK1114622A1 (en) 2008-11-07
HK1095334A1 (en) 2007-05-04
ZA982908B (en) 1999-01-21
EP0971959A1 (en) 2000-01-19
EP1695985A2 (en) 2006-08-30
ES2380575T3 (en) 2012-05-16
DE69841815D1 (en) 2010-09-16
AU740738B2 (en) 2001-11-15
HK1025338A1 (en) 2000-11-10
KR100856995B1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
DE69832970D1 (en) HUMANIZED ANTIBODIES AND METHOD FOR THEIR MANUFACTURE
DK0973804T3 (en) Anti-VEGF antibodies

Legal Events

Date Code Title Description
8364 No opposition during term of opposition